medigraphic.com
Colegio de Medicina Interna de México.

2012, Número 1

<< Anterior Siguiente >>

Med Int Mex 2012; 28 (1)


Neumonía por Mycoplasma pneumoniae: presentación de un caso y breve revisión bibliográfica

Gómez MGA, Durán GJR, Berny CDA, Salcedo RMI

Idioma: Español
Referencias bibliográficas: 40
Paginas: 81-88
Archivo PDF: 302.26 Kb.


RESUMEN

Mycoplasma pneumoniae se reconoce, en todo el mundo, como una causa primaria de neumonía atípica. Además de las infecciones en las vías respiratorias, este organismo también es responsable de un amplio espectro de manifestaciones extrapulmonares, incluidas las enfermedades neurológicas, hepáticas y cardiacas, anemia hemolítica, poliartritis y eritema multiforme. Esta revisión incluye algunos de los aspectos más recientes del conocimiento de este patógeno, características clínicas de la infección, causa de la enfermedad, radiología y diversas herramientas para el diagnóstico, diagnóstico diferencial y tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lui G, Ip M, Lee N, Rainer TH, et al. Role of 'atypical pathogens' among adult hospitalized patients with community-acquired pneumonia. Respirology 2009;14(8):1098-1005.

  2. Smith LG. Mycoplasma pneumonia and its complications. Infect Dis Clin N Am 2010;24:57-60.

  3. Cuncha CB. The First Atypical Pneumonia: The History of the Discovery of Mycoplasma pneumoniae. Infect Dis Clin N Am 2010;24:1-5.

  4. Xiong YH, Deng R, Fu RR, Li DZ, et al. Atypical pathogens in adult patients admitted with community-acquired pneumonia. Zhonghua Jie He He Hu Xi Za Zhi . 2010;33(9):646-650.

  5. Köksal I, Ozlü T, Bayraktar O, Yılmaz G, et al; TUCAP Study Group. Etiological agents of community-acquired pneumonia in adult patients in Turkey; a multicentric, cross-sectional study. Tuberk Toraks 2010;58(2):119-127.

  6. Schneeberger PM, Dorigo-Zetsma JW, van der Zee A, van Bon M, van Opstal JL. Diagnosis of atypical pathogens in patients hospitalized with community-acquired respiratory infection. Scand J Infect Dis. 2004;36(4):269-273.

  7. Ngeow YF, Suwanjutha S, Chantarojanasriri T, Wang F, et al. An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia. Int J Infect Dis 2005;9(3):144-153.

  8. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17(4):697-728.

  9. Rhee SG, Kang SW, Jeong W, Chang TS, et al. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 2005;17(2):183-189.

  10. Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens. Proc Natl Acad Sci 2006;103(17):6724-6729.

  11. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol 2008;3(6):635-648.

  12. Sillis, M. The limitations of IgM assays in the serological diagnosis of Mycoplasma pneumoniae infections. J Med Microbiol 1990;33:253-258.

  13. Baum SJ. Mycoplasma pneumoniae and atypical pneumonia. In: Bennett's principles and practice of infectious diseases. Mandell D, editors. Philadelphia: Elsevier, 2005;2271-2280.

  14. Kashyap S, Sarkar M. Mycoplasma pneumonia: Clinical features and management. Lung India 2010;27(2):75-85.

  15. Narita M. Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection. Pediatr Neurol 2009;41(3):159-166.

  16. Guleria R, Nisar N, Chawla TC, Biswas NR. Mycoplasma pneumoniae and central nervous system complications: a review. J Lab Clin Med 2005;146:55-63.

  17. Nishimura M, Saida T, Kuroki S, et al. Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection. J Neurol Sci 1996;140:91-95.

  18. Fusco C, Bonini E, Soncini G, Frattini D, et al. Transient basal ganglia and thalamic involvement following Mycoplasma pneumoniae infection associated with antiganglioside antibodies. J Child Neurol 2010;25(8):1029-1033.

  19. Lodi G, Resca D, Reverberi R. Fatal cold agglutinin-induced haemolytic anaemia: a case report. J Med Case Reports. 2010;4:252.

  20. Josef D. Schwarzmeier. A potentially fatal complication of Mycoplasma pneumoniae infection: The hemophagocytic syndrome. Respiration 2002;69:14-15.

  21. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008;3(6):635-648.

  22. Hsieh SC, Kuo YT, Chern MS, Chen CY, Chan WP, Yu C. Mycoplasma pneumonia: clinical and radiographic features in 39 children. Pediatr Int. 2007;49(3):363-367.

  23. Reittner P, Müller NL, Heyneman L, Johkoh T, et al. Mycoplasma pneumoniae pneumonia: radiographic and highresolution CT features in 28 patients. AJR Am J Roentgenol 2000;174(1):37-41.

  24. Lind K, Lindhardt BO, Schutten HJ, Blom J, Christiansen C. Serological cross-reactions between M. genitalium and M. pneumoniae. J Clin Microbiol 1984;20:1036-1043.

  25. Beersma MF, Dirven K, van Dam AP, Templeton KE, et al. Evaluation of 12 commercial tests and the complement fixation test for Mycoplasma pneumoniae-specific immunoglobulin G (IgG) and IgM antibodies, with PCR used as the "gold standard". J Clin Microbiol 2005;43(5):2277-2285.

  26. Andreu LM, Molinos AS, Fernandez RG, González SV, Ausina RV. Serologic diagnosis of Mycoplasma pneumoniae infections. Enferm Infect Microbiol Clin 2006;24:19-23.

  27. Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev 2008;32:956-973.

  28. Miyashita N, Matsushima T, Oka M, Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 2006;45(7):419-428.

  29. Waites KB, Crabb DM, Bing X, Duffy LB. In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 2003; 47:161–165.

  30. Waites KB, Crabb DM, Duffy LB. Inhibitory and bactericidal activities of gemifloxacin and other antimicrobials against Mycoplasma pneumoniae. Int J Antimicrob Agents 2003; 21:574–577.

  31. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, et al. Emergence of macrolide resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob Agents Chemother. 2005;49:2302–6.

  32. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48:4624–30.

  33. Beeton ML, Chalker VJ, Kotecha S, Spiller OB. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. J Antimicrob Chemother. 2009 Sep;64(3):529-38.

  34. Xie X, Zhang J. Trends in the rates of resistance of Ureaplasma urealyticum to antibiotics and identification of the mutation site in the quinolone resistance-determining region in Chinese patients. FEMS Microbiol Lett. 2006 Jun;259(2):181-6.

  35. Bebear CM, Renaudin H, Charron A, Gruson D, Lefrancois M, Bebear C. In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinoloneresistant isolates that have been genetically characterized. Antimicrob Agents Chemother. 2000 Sep;44(9):2557-60.

  36. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72.

  37. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the mana gement of community acquired pneumonia in adults: update 2009. Thorax. 2009 Oct;64 Suppl 3:iii1-55.

  38. Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de Castro F; Sociedad Española de Neumología y Cirugía Torácica. [Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR)]. Arch Bronconeumol. 2010 Oct;46(10):543-58. Epub 2010 Sep 15.

  39. Chambert-Loir C, Ouachee M, Collins K, Evrard P, Servais L. Immediate relief of Mycoplasma pneumoniae encephalitis symptoms after intravenous immunoglobulin. Pediatr Neurol. 2009 Nov;41(5):375-7.

  40. Tsai V, Oman J. Stevens-Johnson syndrome after mycoplasma pneumoniae infection. J Emerg Med. 2011 Mar;40(3):324-7.




2020     |     www.medigraphic.com